The prognosis for Acute Myeloid Leukemia (AML) is directly linked to the success of treatment. Since treatment success varies significantly considering both individual patient characteristics and the clinical features of the disease, specifying a precise life expectancy can be misleading. Therefore, evaluating full remission or cure rates for the disease is a more rational approach. While the chance of cure for AML was approximately 10-50% in the 1970s, this rate has approached 70% since the 2010s with the incorporation of stem cell transplantation and targeted intelligent drugs into treatment. This positive development is particularly noticeable for patients under 60 years of age.